A Safety Study of PTI-125 in Healthy Volunteers

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-08-18

Study Completion Date

2018-03-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A Phase I, Single Center, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose, Pharmacokinetic and Safety Study of PTl-125 in Healthy Volunteers

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

PTI-125 for Mild-to-moderate Alzheimer's Disease Patients

NCT03748706

Alzheimer Disease

COMPLETED PHASE2

PTI-125 for Mild-to-moderate Alzheimer's Disease Patients

NCT04079803

Alzheimer Disease

COMPLETED PHASE2

Study Evaluating the Safety, Tolerability and Efficacy of PBT2 in Patients With Early Alzheimer's Disease

NCT00471211

Alzheimer's Disease

COMPLETED PHASE2

A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia

NCT06651567

Agitation Associated With Alzheimer's Dementia

RECRUITING PHASE2

Study of ITI-007 in Healthy Geriatric Volunteers and in Geriatric Patients With Dementia

NCT02078310

Alzheimer's Disease

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This was a Phase I, single center, randomized, double-blind, placebo-controlled, single ascending dose (SAD) study in healthy volunteers, 18 to 45 years of age. A total of twenty-four (24) subjects were enrolled into the study in one of three dose cohorts. Each cohort contained eight subjects; six subjects received PTI-125 and two received placebo. Three doses of PTI-125 oral solution (50, 100, and 200 mg) or placebo solution were administered to respective cohorts.

The study included a screening period (Day -28 to Day -1), an inpatient treatment period (Day 0 through Day 4), and a follow-up visit (Day 7). Subjects reported to the clinic on the day before dosing and were randomized to receive either a single dose of orally administered PTI-125 or placebo. Each dose was administered following an overnight fast of at least 10 hours.

For each dose level, dosing was staggered such that two subjects (one active and one placebo) were dosed prior to the rest of the group. After a minimum of 24 hours and review of all 24-hour safety assessments (electrocardiogram \[ECG\], a brief physical examination, vital signs, and laboratory assessments) an independent Data Safety Monitoring Board/Data Monitoring Committee (DSMB/DMC) determined whether the remaining 6 subjects were to be dosed.

Pharmacokinetic blood samples were obtained prior to dosing and at specified intervals during the study (0-72 hours post-dose). Blood draws for laboratory testing were performed prior to dosing and at 24 hours post dose. After safety assessments of ECG, vital signs, and a brief physical exam at 72 hours, subjects were discharged from the clinic and returned 7 days post-dose for a final safety assessment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alzheimer Disease, Early Onset Alzheimer Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Single center, randomized, double-blind, placebo controlled, SAD study of three escalating doses of PTI-125. A total of 24 healthy subjects enrolled in one of three dose cohorts. Each cohort will contain 8 subjects; six receive PTI-125 and two receive placebo. Three SAD does of PTI-125 oral solution (50, 100 or 200 mg) or placebo solution will be administered.

Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

50 mg PTI-125

Six (6) subjects will receive a single orally administered dose of 50 mg PTI-125 in this cohort.

Group Type ACTIVE_COMPARATOR

50 mg PTI-125

Intervention Type DRUG

PTI-125 50 mg Oral Solution

50 mg PTI-125 Placebo

Two (2) subjects will receive a single orally administered dose of 50 mg Placebo PTI-125 in this cohort.

Group Type PLACEBO_COMPARATOR

50 mg PTI-125

Intervention Type DRUG

PTI-125 50 mg Oral Solution

100 mg PTI-125

Six (6) subjects will receive a single orally administered dose of 100 mg PTI-125 in this cohort.

Group Type ACTIVE_COMPARATOR

100 mg PTI-125

Intervention Type DRUG

PTI-125 100 mg Oral Solution

100 mg PTI-125 Placebo

Two (2) subjects will receive a single orally administered dose of 100 mg Placebo PTI-125 in this cohort.

Group Type PLACEBO_COMPARATOR

100 mg PTI-125

Intervention Type DRUG

PTI-125 100 mg Oral Solution

200 mg PTI-125

Six (6) subjects will receive a single orally administered dose of 200 mg PTI-125 in this cohort.

Group Type ACTIVE_COMPARATOR

200 mg PTI-125

Intervention Type DRUG

PTI-125 200 mg Oral Solution

200 mg PTI-125 Placebo

Two (2) subjects will receive a single orally administered dose of 200 mg Placebo PTI-125 in this cohort.

Group Type PLACEBO_COMPARATOR

200 mg PTI-125

Intervention Type DRUG

PTI-125 200 mg Oral Solution

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

50 mg PTI-125

PTI-125 50 mg Oral Solution

Intervention Type DRUG

100 mg PTI-125

PTI-125 100 mg Oral Solution

Intervention Type DRUG

200 mg PTI-125

PTI-125 200 mg Oral Solution

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female subjects between 18 and 45 years of age, inclusive.
* The subject has a body mass index (BMI) within 18-30 kg/m2 (inclusive).
* The subject is in good health as determined by medical history and physical examination and clinical laboratory parameters.
* The subject is willing and able to speak, read, and understand English and provide written informed consent.
* The subject is a non-smoker for at least 12 months. If a former smoker, the reason for stopping must be evaluated.
* Females who are physically incapable of childbearing defined as postmenopausal, or surgically sterile (hysterectomy, bilateral tubal ligation, bilateral oophorectomy or an Essure procedure). Appropriate documentation (ex; medical record) of the surgical sterilization procedure to be obtained and held within the subject's study file.
* The subject must agree to comply with the drawing of blood samples for the PK assessments.
* The subject is willing and able to comply with all testing and requirements defined in the protocol.
* The subject is willing and able to remain at the study site unit for the duration of the confinement period and return for the outpatient visit.

Exclusion Criteria

* The subject has any relevant deviations from normal in physical examination, electrocardiogram (ECG), or clinical laboratory tests, as evaluated by the investigator.
* The subject has had a clinically significant illness within 30 days of Check-in.
* The subject has a history of significant neurological, hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, or metabolic disease.
* The subject has used any prescription medication within 14 days of dosing or overthe- counter (OTC) medication within 48 h of dosing or intends to use any prescription medication or OTC medication during the study that may interfere with the evaluation of study medication.
* The subject has used alcohol, caffeine or xanthine-containing products 48 h before dosing or intends to use any of these products during the study.
* The subject has used grapefruit, grapefruit juice, or grapefruit-containing products days before dosing or intends to use any of these products during the study.
* The subject has a history of substance abuse or a positive ethanol breath test, urine cotinine, or urine drug screen at screening or at check-in. The subject has a positive serum hepatitis B surface antigen or positive HCV antibody test at the Screening Visit.
* The subject has a positive HIV test at the Screening Visit.
* Female subject is pregnant or breastfeeding.
* The subject has received an investigational drug within 30 days of Check-in.
* The subject has donated or lost a significant volume of blood (\>450 mL) within 4 weeks prior to the study.
* The subject is unwilling to reside in the study unit for the duration of the study or to cooperate fully with the investigator or site personnel.
* The subject has an AST/ALT or total bilirubin greater than the ULN. One repeat test will be allowed.

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes